title: [Assessment of serum IgG activity correlation against cyclic citrullinated peptide antibodies, topoisomerase I and centromere proteins in Mexican patients with progressive systemic sclerosis].
abstract: OBJECTIVE
  To evaluate sera titers for antibodies anti-cyclic citrullinated peptide and their correlation against sera levels of anti-topoisomerase I and anti-centromere antibodies in Mexican patients with systemic sclerosis.
  
  
  METHODS
  Consecutive outpatients with systemic sclerosis who attending to rheumatology clinic at a second level hospital facility. The antibodies anti-cyclic citrullinated peptide, anti-topoisomerase I and anti-centromere were determined by enzymatic immunoassay (ELISA).
  
  
  METHODS
  Spearman for correlation between numerical variables with nonparametric distribution. Fisher exact test or chi2 to compare proportions and Student t test for dimensional variables.
  
  
  RESULTS
  Thirty female patients were included; aged 53 +/- 13, the disease duration at the time of the study was 10 +/- 9. Twenty-three patients (77%) exhibited diffuse disease. Anti-centromere, anti-topoisomerase I, and anti-cyclic citrullinated peptide were detected in nine, nine and three patients respectively. The correlation analysis showed the independence of autoantibodies anti-centromere and anti-topoisomerase I with respect to the levels of anti-cyclic citrullinated peptide.
  
  
  CONCLUSIONS
  This study confirms the low frequency of anti-cyclic citrullinated peptide antibodies in patients with systemic sclerosis. A lack of correlation between autoantibodies considered as "mutually excluded" anti-topoisomerase I and anti-centromere, indicating that the analysis of the relevance for anti-cyclic citrullinated peptide in systemic sclerosis must include other clinical and serological variables.
authors.affiliation: Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, IMSS, Guadalajara, Jalisco, México.
authors.forename: Alberto D
authors.initials: AD
authors.lastname: Rocha-Muñoz
authors.forename: Laura
authors.initials: L
authors.lastname: González-López
authors.forename: Rebeca
authors.initials: R
authors.lastname: Peguero-Gómez
authors.forename: Erika A
authors.initials: EA
authors.lastname: Aguilar-Chávez
authors.forename: Alberto I
authors.initials: AI
authors.lastname: Villa-Manzano
authors.forename: Esther
authors.initials: E
authors.lastname: Corona-Sánchez
authors.forename: Silvia
authors.initials: S
authors.lastname: Galván-Méndez
authors.forename: Carmen
authors.initials: C
authors.lastname: Presiado-Sánchez
authors.forename: José C
authors.initials: JC
authors.lastname: Vázquez-Jiménez
authors.forename: Carlos
authors.initials: C
authors.lastname: Riebeling
authors.forename: Mario
authors.initials: M
authors.lastname: Salazar-Páramo
authors.forename: Jorge I
authors.initials: JI
authors.lastname: Gámez-Nava
authors.forename: Arnulfo
authors.initials: A
authors.lastname: Nava
mesh_terms: D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D001327:Autoimmune Diseases / Q000097:blood / Q000276:immunology*; D002503:Centromere / Q000276:immunology*; D004264:DNA Topoisomerases, Type I / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood* / Q000276:immunology; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology*; D045743:Scleroderma, Diffuse / Q000097:blood / Q000453:epidemiology / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; D007074:Immunoglobulin G; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide; D004264:DNA Topoisomerases, Type I